Comparative cost-effectiveness of HPV mRNA and DNA testing for anal cancer screening in MSM living with HIV: a model-based study
Anal cancer incidence is increasing among men who have sex with men (MSM) living with HIV, driven by persistent high-risk (HR) HPV infection. HPV mRNA testing may offer higher specificity for detecting high-grade squamous intraepithelial lesions (HSIL) than cytology or HPV DNA testing, with potential economic implications. We evaluated the cost-effectiveness of screening strategies combining HPV biomarkers and post-high-resolution anoscopy (HRA) management. A Markov model simulated a cohort of MSM living with HIV to assess 45 screening strategies varying by algorithm (cytology, co-testing, HPV reflex), HPV assay (DNA-hybridization, DNA-PCR, mRNA), and post-HRA management (follow-up, infrared coagulation [IRC], trichloroacetic acid [TCA]). Outcomes included HSIL and anal cancer cases, quality-adjusted life-years (QALYs), costs, and incremental cost-effectiveness ratios (ICERs). Strategies involving treatment reduced anal cancer incidence by 43–69% compared with no screening, with greater reductions for co-testing. Cytology was the most cost-effective option at €25 per test. At €6, co-testing became competitive, particularly with HR-HPV assays—DNA-hybridization (€13,203/QALY) and mRNA (€14,482/QALY). All optimal strategies included TCA. Anal cancer screening in MSM living with HIV is effective and cost-effective. Co-testing with cytology and HR-HPV assays—whether DNA or mRNA—combined with post-HRA treatment provided the greatest health benefits, while its cost-effectiveness depended strongly on HPV test cost and became favorable at lower HPV test costs. HPV mRNA-based approaches provided a comparable and viable alternative to HPV DNA.
Authors
- Alexandra Montoliu (ORCID: https://orcid.org/0000-0002-4251-7062)
- María Saumoy (ORCID: https://orcid.org/0000-0002-0047-1991)
- David Gómez-Guillén (ORCID: https://orcid.org/0000-0003-1787-6482)
- Ana Silva‐Klug (ORCID: https://orcid.org/0000-0003-4660-534X)
- Loris Trenti (ORCID: https://orcid.org/0000-0003-3153-5115)
- Mireia Díaz (ORCID: https://orcid.org/0000-0001-9360-4548)
- Sònia Paytubi (ORCID: https://orcid.org/0000-0002-5392-953X)
- Núria Baixeras
- Daniel Podzamczer (ORCID: https://orcid.org/0000-0001-7090-3561)
- Laia Alemany
- Montserrat Torres
Institutions
- Instituto de Salud Carlos III (ES)
- Bellvitge University Hospital (ES)
- Institut d'Investigació Biomédica de Bellvitge (ES)
- Institut Català d'Oncologia (ES)
- Barcelona Institute for Global Health (ES)
- Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (ES)
- Fundació Lluita contra les Infeccions (ES)
- Medical Research Network (US)
Publication Details
- Journal
- Scientific Reports
- Published
- 2026-11-19
- DOI
- https://doi.org/10.1038/s41598-026-75472-6
- Primary Topic
- Cervical Cancer and HPV Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00